Correlation Between Neuropace and Sharps Technology

Can any of the company-specific risk be diversified away by investing in both Neuropace and Sharps Technology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neuropace and Sharps Technology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neuropace and Sharps Technology, you can compare the effects of market volatilities on Neuropace and Sharps Technology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neuropace with a short position of Sharps Technology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neuropace and Sharps Technology.

Diversification Opportunities for Neuropace and Sharps Technology

-0.74

Correlation Coefficient

Neuropace  Sharps Technology

Pay attention - limited upside

The 3 months correlation between Neuropace and Sharps is -0.74. Overlapping area represents the amount of risk that can be diversified away by holding Neuropace and Sharps Technology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sharps Technology and Neuropace is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neuropace are associated (or correlated) with Sharps Technology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sharps Technology has no effect on the direction of Neuropace i.e., Neuropace and Sharps Technology go up and down completely randomly.

Pair Corralation between Neuropace and Sharps Technology

Given the investment horizon of 90 days Neuropace is expected to generate 0.29 times more return on investment than Sharps Technology. However, Neuropace is 3.49 times less risky than Sharps Technology. It trades about 0.04 of its potential returns per unit of risk. Sharps Technology is currently generating about -0.15 per unit of risk. If you would invest  1,119  in Neuropace on December 4, 2024 and sell it today you would earn a total of  62.00  from holding Neuropace or generate 5.54% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Neuropace  vs.  Sharps Technology

Neuropace

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Neuropace are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Neuropace may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Sharps Technology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Sharps Technology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Neuropace and Sharps Technology

The main advantage of trading using opposite Neuropace and Sharps Technology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neuropace position performs unexpectedly, Sharps Technology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sharps Technology will offset losses from the drop in Sharps Technology's long position.

The idea behind Neuropace and Sharps Technology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.